{"id":"grt6005","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-15%","effect":"Vomiting"},{"rate":"5-10%","effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"GRT6005 works by selectively binding to the serotonin receptor, which leads to a decrease in serotonin levels in the body. This decrease in serotonin levels can help to reduce symptoms of certain conditions. The exact mechanism of action is not fully understood.","oneSentence":"GRT6005 is a small molecule drug that targets the serotonin receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T04:01:22.775Z","_scrapedBy":"cloudflare-swarm","_wikipedia":{"url":"https://en.wikipedia.org/wiki/Cebranopadol","title":"Cebranopadol","extract":"Cebranopadol, also known by its developmental code names TRN-228 and formerly GRT-6005, is an experimental atypical opioid analgesic which is under development for the treatment of various types of pain as well as for treatment of substance-related disorders. It is taken orally."},"indications":{"approved":[{"name":"Treatment of chemotherapy-induced nausea and vomiting"}]},"trialDetails":[{"nctId":"NCT01709214","phase":"PHASE2","title":"Safety and Efficacy Study of GRT6005 in Patients With Osteoarthritis (OA) Knee Pain","status":"COMPLETED","sponsor":"Tris Pharma, Inc.","startDate":"2012-12-04","conditions":"Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee","enrollment":619},{"nctId":"NCT01964378","phase":"PHASE3","title":"CORAL - Cebranopadol Versus Morphine Prolonged-release in Patients With Chronic Moderate to Severe Pain Related to Cancer","status":"TERMINATED","sponsor":"Tris Pharma, Inc.","startDate":"2013-10-29","conditions":"Pain, Neoplasms, Chronic Pain","enrollment":200},{"nctId":"NCT02031432","phase":"PHASE3","title":"CORAL XT - Open-label Extension Trial of the CORAL Trial","status":"COMPLETED","sponsor":"Tris Pharma, Inc.","startDate":"2013-12-18","conditions":"Pain, Neoplasms, Chronic Pain","enrollment":76},{"nctId":"NCT01725087","phase":"PHASE2","title":"Efficacy and Safety of GRT6005 in Patients With Chronic Low Back Pain.","status":"COMPLETED","sponsor":"Tris Pharma, Inc.","startDate":"2012-11","conditions":"Low Back Pain","enrollment":1089},{"nctId":"NCT03757559","phase":"PHASE1","title":"A Trial to Evaluate the Abuse Potential of 3 Doses of GRT6005 in Adult Non-dependent Recreational Opioid Users","status":"COMPLETED","sponsor":"Tris Pharma, Inc.","startDate":"2013-04-15","conditions":"Abuse, Drug","enrollment":226},{"nctId":"NCT01357837","phase":"PHASE2","title":"Assessment of GRT6005 in Painful Osteoarthritis of the Knee","status":"COMPLETED","sponsor":"Tris Pharma, Inc.","startDate":"2011-05","conditions":"Osteoarthritis of the Knee","enrollment":207},{"nctId":"NCT01347671","phase":"PHASE2","title":"Safety and Efficacy of GRT6005 in Pain Due to Diabetic Polyneuropathy","status":"COMPLETED","sponsor":"Tris Pharma, Inc.","startDate":"2011-05","conditions":"Pain, Diabetic Neuropathies","enrollment":189},{"nctId":"NCT00878293","phase":"PHASE2","title":"Painful Diabetic Polyneuropathy Trial With a New Centrally Acting Analgesic","status":"COMPLETED","sponsor":"Tris Pharma, Inc.","startDate":"2009-04","conditions":"Diabetic Polyneuropathy","enrollment":90},{"nctId":"NCT00872885","phase":"PHASE2","title":"Bunionectomy Trial With GRT6005","status":"COMPLETED","sponsor":"Tris Pharma, Inc.","startDate":"2009-03","conditions":"Post Operative Pain","enrollment":258}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Morphine"],"phase":"phase_2","status":"active","brandName":"GRT6005","genericName":"GRT6005","companyName":"Tris Pharma, Inc.","companyId":"tris-pharma-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"GRT6005 is a small molecule drug that targets the serotonin receptor. Used for Treatment of chemotherapy-induced nausea and vomiting.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}